Company news
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A (SZSE:002603) news
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Jul 6, 2026: Shijiazhuang Yiling Pharmaceutical Says Subsidiary's…
Press releases & updates
Shijiazhuang Yiling Pharmaceutical Says Subsidiary's Irbesartan Approved
July 6, 2026
Shijiazhuang Yiling Pharmaceutical : Net profit rose 277.56% to ¥1.29 billion on 20.24% revenue growth, with robust cash flow
April 27, 2026
Shijiazhuang Yiling Pharmaceutical Sees 2025 Net Profit 1.2-1.3 Billion Yuan
January 22, 2026
Shijiazhuang Yiling Pharmaceutical Co: Net profit soared 80.33% to ¥1.00 billion despite a 7.82% revenue decline
October 28, 2025
Yiling Pharmaceutical Q3 Net Profit Up 1264.6% Y/Y
October 27, 2025
Shijiazhuang Yiling Pharmaceutical Co: Net profit rose 26% to ¥669 million despite a 12% revenue drop, with strong cash flow
August 28, 2025
Shijiazhuang Yiling Pharmaceutical Co: Net profit grew 7.25% year-over-year in Q1 2025 despite a 6.52% revenue drop
April 29, 2025
Shijiazhuang Yiling Pharmaceutical Co: 2024 net loss driven by sales drop, inventory write-downs, and high R&D; cost control prioritized
April 28, 2025
Shijiazhuang Yiling Pharmaceutical Co: Revenue and profit declined sharply year-over-year, but operating cash flow improved
October 28, 2024
Shijiazhuang Yiling Pharmaceutical Co: Revenue and profit declined sharply, but R&D and market leadership in core products remain strong
August 27, 2024